Soligenix Inc. (NASDAQ:SNGX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday. They currently have a $5.50 price target on the biopharmaceutical company’s stock, down from their prior price target of $11.00. HC Wainwright’s price objective would suggest a potential upside of 163.16% from the company’s previous close.

Separately, Maxim Group set a $5.00 price target on shares of Soligenix and gave the stock a “buy” rating in a research note on Tuesday, October 31st.

Soligenix (NASDAQ:SNGX) opened at $2.09 on Monday. Soligenix has a 12 month low of $1.74 and a 12 month high of $5.08.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.15. The business had revenue of $1.82 million during the quarter, compared to the consensus estimate of $1.36 million. Soligenix had a negative net margin of 90.93% and a negative return on equity of 100.40%. sell-side analysts anticipate that Soligenix will post -1.52 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.